A Phase 3 interventional study of Laboratory Biomarker Analysis and Recombinant Human Papillomavirus Nonavalent Vaccine in AIDS-Related Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia and HIV Infection, sponsored by AIDS Malignancy Consortium. Completed at 6 sites in 5 countries. Open to female participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by AIDS Malignancy Consortium · Phase 3, Interventional, and Prevention
Among 29 studies in HIV Infections by AIDS Malignancy Consortium — 3 open to participants now, 4 under way, none of them phase 3. HIV Infections · AIDS Malignancy Consortium.
Among the 29 studies in HIV Infections by AIDS Malignancy Consortium, this one is the 2nd largest by enrollment of the 16 interventional ones, is the only one that started in 2019, is one of 4 in phase 3, and was the 20th registered.
4,734 studies on the registry are indexed under HIV Infections; 244 are open to participants now.
This study's enrollment of 535 is above the median of 80 across 3,489 interventional studies indexed under HIV Infections.
Browse HIV Infections studies →3 of the 29 studies in HIV Infections by AIDS Malignancy Consortium are open now, in 1 country. Each count lists the studies.
Of the 158 HIV Infections studies recruiting now, 104 (66%) set no upper age limit and 41 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 25 Years and older · female · no healthy volunteers.
The full table on the hub →29 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2019.
Median enrollment 66 across the 16 interventional studies, 82 across the 13 observational. Of the 21 that completed or were terminated, 13 (62%) have results posted.
AIDS Malignancy Consortium is the lead sponsor of 61 studies on the registry; 9 are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 9 (90%) have results posted.
1 of the studies in HIV Infections by AIDS Malignancy Consortium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04949464AIDS Malignancy ConsortiumImpact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | 2026-12-31 |
Among the 29 studies in HIV Infections by AIDS Malignancy Consortium, from their registry updates:
This randomized phase III trial studies how well human papillomavirus (HPV) vaccine therapy works in reducing high-grade cervical lesions in patients with human immunodeficiency virus (HIV) and HPV. Vaccines made from HPV peptides or antigens may help the body build an effective immune response to kill the HPV virus and prevent cervical lesions from developing or coming back after being removed.
At screening, potential participants will be tested for cervical human papillomavirus (HPV) infection (GeneXpert hrHPV assay and HPV DNA PCR) and undergo cervical colposcopy to confirm the absence of cervical cancer. If eligible, the participant will be randomized to receive either the 9-valent HPV vaccine or saline placebo.
Participants will return 4 and 26 weeks later for the second dose of vaccine or placebo. At week 4, participants will have cervical colposcopy and undergo cryotherapy or loop electrosurgical excisional procedure (LEEP) as appropriate. Participants undergoing cervical cryotherapy will have cervical biopsies before the treatment. Participants will be followed with HPV testing (Gene Xpert and HPV DNA PCR) at weeks 26, 52, 78, and 104, and will have cervical cytology and colposcopy with biopsies at weeks 26, 52, and 104.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive Recombinant Human Papillomavirus Nonavalent Vaccine (Gardasil 9) IM at baseline, 4, and 26 weeks in the absence of disease progression or unacceptable toxicity, with sample collection for Laboratory Biomarker Analysis.
Other: Laboratory Biomarker Analysis · Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
Patients receive saline placebo vaccine IM at baseline, 4, and 26 weeks, with sample collection for Laboratory Biomarker Analysis.
Other: Laboratory Biomarker Analysis · Other: Saline
Correlative studies
Given IM
Also known as: Gardasil 9, Nonavalent HPV VLP Vaccine, Recombinant HPV Nonavalent Vaccine, Recombinant Human Papillomavirus 9-valent Vaccine, Recombinant HPV 9-valent Vaccine
Given IM
Also known as: Sodium Chloride 0.9%
Occurrence of Cervical High-grade Squamous Intraepithelial Lesions (HSIL) or Cervical Cancer
For each arm (vaccine and placebo), the HSIL or cancer event rate will be estimated using its point estimate and 95% Poisson confidence intervals. Poisson regression analyses will be used to compare the two arms with respect to event rate. In addition, time to event from week 4 to 52 will be described using the Kaplan-Meier method for each arm, and the two arms will be compared with respect to time to event using the log-rank test.
Time frame: After week 4 study visit to week 52 post-randomization
Occurrence of Cervical HSIL or Invasive Cancer From Weeks 52-104
The event rate for each arm from week 52 to week 104 for women who are event-free at 52 weeks will be estimated using its point estimate and 95% Poisson confidence interval. Poisson regression will be used to compare the two groups with respect to the event rate from week 52 to 104.
Time frame: After week 52 to week 104
Predictors of Sustained Absence of Cervical HSIL Through Week 104 and HPV Clearance
Role of baseline types and quantity of HPV, presence of HSIL at baseline, cryotherapy vs. LEEP, CD4+ cell count, plasma HIV-1 RNA, ART use, age, sexual behavior, and vaccination use will be investigated. Poisson regression analyses will be used to determine if these factors are associated with of sustained absence of cervical HSIL and clearance of HPV infections after cryotherapy or LEEP. These analyses will also control for use of LEEP or cryotherapy.
Time frame: At baseline through week 104
Incident Cervical Vaccine Type HPV Infections
Incident cervical vaccine type HPV infections are defined as HPV infections detected at 2 consecutive timepoints and assessed using type specific HPV DNA polymerase chain reaction (PCR) Vaccine and placebo participants will be compared with respect to these proportions using the chi-square test corrected for continuity.
Time frame: Up to week 104
Abnormal Cervical Cytology
The proportion of women with abnormal cervical cytology at baseline, week 26, 52, and 104 will be reported and compared between arms.
Time frame: Baseline, week 26, 52, and 104
Prevalent Vulvar HSIL or Cancer
The prevalence of vulvar HSIL or cancer at baseline will be estimated using the binomial proportion and its 95% confidence interval.
Time frame: Up to week 4
Incident Vulvar HSIL or Cancer
The proportion of women who acquire vulvar HSIL or cancer among those negative for vulvar HSIL or cancer at baseline for both intervention arms will be estimated as a binomial proportion for both groups. The chi-square test corrected for continuity will be used to compare arms with respect to the proportions who acquire vulvar HSIL during the study.
Time frame: Up to week 104
Number of Participants Stratified by the Presence or Absence of Incident Vulvar HSIL/Cancers.
Due to insufficient number of participants with outcome assessments, association (Logistic regression) analysis with clinical and demographic factors was not performed
Time frame: Up to week 104
HPV Type Distributions
Will characterize the HPV type distribution in baseline histology specimens and compare this to the types observed among incident cervical and vulvar HSIL lesions. Specifically, will compare the number and proportion of vaccine-type and non-vaccine type lesions between arms.
Time frame: Up to week 104
HPV Strain Variant Analysis of Cervical and Vulvar HSIL Specimens
For study participants who have the same HPV type in HSIL specimens at baseline and follow-up time points, sequencing will be performed to determine whether or not HSIL is caused by an identical HPV strain. Will use all available pairs of baseline and follow-up HSIL caused by the same HPV type. Will report the proportion of these pairs with the same HPV strain in both treatment arms. Additionally, will report the rates of HSIL caused by new vaccine type infections. We will compare the two study groups using a chi-square test. This will be a descriptive analysis only as no sufficient data on which to power this analysis.
Time frame: Up to week 104
Tissue Microarray Library of Cervical Specimens for Biomarker Analysis and Discovery
Specimen banking objective. There is no pre-specified statistical analysis plan for this objective. Any future studies using these specimens will need to receive separate approval by NCI and CTEP.
Time frame: Up to week 104
hrHPV Type Distribution in the Anus
McNemar's chi-square test to compare the prevalence of that type in the anus and cervix will be used. For each hrHPV type, chi-square analyses will be used to compare the two HPV vaccination groups with respect to the distribution of that type in the (anus, cervix). Will report the proportion of incident cervical infections that were preceded by anal detection of the same type.
Time frame: Up to week 104
hrHPV Type Prevalence in the Anus
McNemar's chi-square test to compare the prevalence of that type in the anus and cervix will be used. For each hrHPV type, chi-square analyses will be used to compare the two HPV vaccination groups with respect to the distribution of that type in the (anus, cervix). Will report the proportion of incident cervical infections that were preceded by anal detection of the same type.
Time frame: Up to week 104
Vaccine-induced Antibody Titers
Will explore the antibody titers for the vaccine type found in the HSIL in these women as compared to those without HSIL caused by that type. Analysis of vaccine titers between those with incident vaccine type HPV infections that persist for 2 or more study visits and those that do not will be performed.
Time frame: Up to week 104
| Milestone | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| Started | 265 | 270 |
| Discontinued before the initiation of treatment | 2 | 1 |
| Intention to treat population | 238 | 252 |
| Per protocol population | 232 | 249 |
| Completed | 225 | 237 |
| Not completed | 40 | 33 |
For each arm (vaccine and placebo), the HSIL or cancer event rate will be estimated using its point estimate and 95% Poisson confidence intervals. Poisson regression analyses will be used to compare the two arms with respect to event rate. In addition, time to event from week 4 to 52 will be described using the Kaplan-Meier method for each arm, and the two arms will be compared with respect to time to event using the log-rank test.
| events per 100 person-years | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| Intention to treat set | 16.4 (11.6 to 23.0) | 21.3 (15.9 to 28.6) |
| Per protocol set | 16.8 (12.0 to 23.7) | 21.6 (16.1 to 29.0) |
The event rate for each arm from week 52 to week 104 for women who are event-free at 52 weeks will be estimated using its point estimate and 95% Poisson confidence interval. Poisson regression will be used to compare the two groups with respect to the event rate from week 52 to 104.
| events per 100 person-years | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo |
|---|---|---|
| Occurrence of Cervical HSIL or Invasive Cancer From Weeks 52-104 | 4.87 (2.53 to 9.34) | 4.90 (2.55 to 9.41) |
Role of baseline types and quantity of HPV, presence of HSIL at baseline, cryotherapy vs. LEEP, CD4+ cell count, plasma HIV-1 RNA, ART use, age, sexual behavior, and vaccination use will be investigated. Poisson regression analyses will be used to determine if these factors are associated with of sustained absence of cervical HSIL and clearance of HPV infections after cryotherapy or LEEP. These analyses will also control for use of LEEP or cryotherapy.
Results for this outcome have not been posted.
Incident cervical vaccine type HPV infections are defined as HPV infections detected at 2 consecutive timepoints and assessed using type specific HPV DNA polymerase chain reaction (PCR) Vaccine and placebo participants will be compared with respect to these proportions using the chi-square test corrected for continuity.
Results for this outcome have not been posted.
The proportion of women with abnormal cervical cytology at baseline, week 26, 52, and 104 will be reported and compared between arms.
| Participants | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| Baseline — NILM | 97 | 89 |
| Baseline — >=ASCUS | 164 | 174 |
| Week 26 — NILM | 160 | 160 |
| Week 26 — >=ASCUS | 74 | 92 |
| Week 52 — NILM | 167 | 173 |
| Week 52 — >=ASCUS | 55 | 60 |
| Week 104 — NILM | 174 | 180 |
| Week 104 — >=ASCUS | 46 | 50 |
The prevalence of vulvar HSIL or cancer at baseline will be estimated using the binomial proportion and its 95% confidence interval.
| Participants | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo |
|---|---|---|
| Prevalent Vulvar HSIL or Cancer | 2 | 4 |
The proportion of women who acquire vulvar HSIL or cancer among those negative for vulvar HSIL or cancer at baseline for both intervention arms will be estimated as a binomial proportion for both groups. The chi-square test corrected for continuity will be used to compare arms with respect to the proportions who acquire vulvar HSIL during the study.
| Participants | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| Incident Vulvar HSIL or Cancer | 1 | 0 |
Due to insufficient number of participants with outcome assessments, association (Logistic regression) analysis with clinical and demographic factors was not performed
| Participants | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| Participants with incident vulvar HSIL/Cancer | 1 | 0 |
| Participants with no incident vulvar HSIL/Cancer | 1 | 3 |
Will characterize the HPV type distribution in baseline histology specimens and compare this to the types observed among incident cervical and vulvar HSIL lesions. Specifically, will compare the number and proportion of vaccine-type and non-vaccine type lesions between arms.
Results for this outcome have not been posted.
For study participants who have the same HPV type in HSIL specimens at baseline and follow-up time points, sequencing will be performed to determine whether or not HSIL is caused by an identical HPV strain. Will use all available pairs of baseline and follow-up HSIL caused by the same HPV type. Will report the proportion of these pairs with the same HPV strain in both treatment arms. Additionally, will report the rates of HSIL caused by new vaccine type infections. We will compare the two study groups using a chi-square test. This will be a descriptive analysis only as no sufficient data on which to power this analysis.
Results for this outcome have not been posted.
Specimen banking objective. There is no pre-specified statistical analysis plan for this objective. Any future studies using these specimens will need to receive separate approval by NCI and CTEP.
Results for this outcome have not been posted.
McNemar's chi-square test to compare the prevalence of that type in the anus and cervix will be used. For each hrHPV type, chi-square analyses will be used to compare the two HPV vaccination groups with respect to the distribution of that type in the (anus, cervix). Will report the proportion of incident cervical infections that were preceded by anal detection of the same type.
Results for this outcome have not been posted.
McNemar's chi-square test to compare the prevalence of that type in the anus and cervix will be used. For each hrHPV type, chi-square analyses will be used to compare the two HPV vaccination groups with respect to the distribution of that type in the (anus, cervix). Will report the proportion of incident cervical infections that were preceded by anal detection of the same type.
Results for this outcome have not been posted.
Will explore the antibody titers for the vaccine type found in the HSIL in these women as compared to those without HSIL caused by that type. Analysis of vaccine titers between those with incident vaccine type HPV infections that persist for 2 or more study visits and those that do not will be performed.
Results for this outcome have not been posted.
Collected over AE data is based on all study follow-ups until week 104. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm I, Recombinant HPV 9-valent Vaccine | 4/265 (1.5%) | 16/265 (6%) | 20/265 (7.5%) |
| Arm II, Saline | 3/270 (1.1%) | 20/270 (7.4%) | 22/270 (8.1%) |
| Event | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| NEOPLASMS BENIGN, MALIGNANT AND UNSPECIFIED (INCL CYSTS AND POLYPS) - OTHERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/265 | 8/270 |
| PREGNANCY LOSSPregnancy, puerperium and perinatal conditions | 2/265 | 0/270 |
| ANEMIABlood and lymphatic system disorders | 1/265 | 1/270 |
| BLOOD AND LYMPHATIC SYSTEM DISORDERS - OTHERBlood and lymphatic system disorders | 1/265 | 0/270 |
| GASTROINTESTINAL DISORDERS - OTHERGastrointestinal disorders | 1/265 | 0/270 |
| SEPSISInfections and infestations | 1/265 | 0/270 |
| SEPSISInjury, poisoning and procedural complications | 1/265 | 0/270 |
| HYPOGLYCEMIAMetabolism and nutrition disorders | 1/265 | 0/270 |
| PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS - OTHERPregnancy, puerperium and perinatal conditions | 1/265 | 0/270 |
| SURGICAL AND MEDICAL PROCEDURES - OTHERSurgical and medical procedures | 1/265 | 1/270 |
| Event | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline |
|---|---|---|
| PREGNANCY, PUERPERIUM AND PERINATAL CONDITIONS - OTHERPregnancy, puerperium and perinatal conditions | 9/265 | 12/270 |
| HYPERTENSIONVascular disorders | 7/265 | 6/270 |
| SURGICAL AND MEDICAL PROCEDURES - OTHERSurgical and medical procedures | 0/265 | 2/270 |
| ANEMIABlood and lymphatic system disorders | 1/265 | 1/270 |
| SOFT TISSUE NECROSIS LOWER LIMBMusculoskeletal and connective tissue disorders | 1/265 | 0/270 |
| DIZZINESSNervous system disorders | 1/265 | 0/270 |
| VAGINAL DISCHARGEReproductive system and breast disorders | 1/265 | 0/270 |
| BRONCHIAL OBSTRUCTIONRespiratory, thoracic and mediastinal disorders | 0/265 | 1/270 |
All randomized participants
| Age, Continuous(years) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| Median | 38.0 (32.9 to 44.2) | 39.5 (33.1 to 44.6) | 39.0 (33.0 to 44.4) |
| Age, Customized(Participants) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| <=35 | 93 | 85 | 178 |
| 35.1-45 | 115 | 126 | 241 |
| 45.1-65 | 57 | 59 | 116 |
| Sex/Gender, Customized(Participants) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| Female | 265 | 270 | 535 |
| Ethnicity (NIH/OMB)(Participants) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 179 | 179 | 358 |
| Unknown or Not Reported | 86 | 90 | 176 |
| Race (NIH/OMB)(Participants) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 184 | 181 | 365 |
| White | 1 | 0 | 1 |
| More than one race | 0 | 2 | 2 |
| Unknown or Not Reported | 80 | 87 | 167 |
| CD4+ cells nadir at baseline(Participants) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| <200 cells per cubic mm | 33 | 43 | 76 |
| >=200 cells per cubic mm | 82 | 72 | 154 |
| Not known | 150 | 155 | 305 |
| Median CD4+ nadir at baseline(cells per cubic millimeters) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| Median | 256.0 (143.0 to 389.0) | 242.5 (141.0 to 369.0) | 247.0 (142.0 to 374.0) |
| HIV viral load(Participants) | Arm I, Recombinant HPV 9-valent Vaccine | Arm II, Saline Placebo | Total |
|---|---|---|---|
| ≥200 copies/mL | 15 | 14 | 29 |
| <200 copies/mL | 249 | 255 | 504 |
| Missing data | 1 | 1 | 2 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Papillomavirus Recombinant Vaccine nonavalent
AIDS Malignancy Consortium